here is no doubt that the recently published decision postmenopausal healthy women. The average age of the parand results from the Women's Health Initiative (WHI) ticipants is 63 years, and the age range is 50-79 years (45% will have an impact on postmenopausal women, their were in their 60s and 21% in their 70s 
Thyterectombiedwstromen.and proges arm was discontinued icant menopausal symptoms (especially hot flushing) were exThe combined estrogen and progestin arm was discontinued cuddfo th WHwihmashttenmbrf after an average of 5 produced "more modest changes." The numbers and confievents. The recent reports make an argument that the optimal dence intervals were not provided. approach to postmenopausal hormone therapy is to start treatIt seems that the breast cancer results are heavily influenced ment close to menopause, avoiding a significant period of by years 4 and 5. Remember that the growth of breast tumors exposure to low estrogen levels before beginning therapy. And is slow (it takes 10 years for a malignant cell to become there continues to be good reason (a combination of biologic clinically detectable at 1 cm diameter). The WHI breast cancer data and uniform agreement in a large number of observational results are consistent with hormonal stimulation of preexisting studies) to believe that hormone therapy has a beneficial role in tumors. The hazard risk returned almost to 1.0 in year 6. the primary prevention of coronary artery disease, a beneficial Case-control and cohort studies have uniformly observed a cardiovascular effect in younger postmenopausal women withreduced nsk of dying of breast cancer in women whose cancer out apparent atherosclerosis.
was diagnosed during their use of hormone therapy. This is not The results of the Heart and Estrogen/progestin Replaceonly due to greater use of mammography, but it also reflects ment Study 11 indicate that the increased risk ofvenous thromlower grade and stage disease in hormone users, a finding that boembolism associated with hormone therapy is concentrated is consistent with accelerated growth of preexisting tumors. In in the first two years of use (in fact, the increase was statistically the WHI results, there were only three deaths from breast significant only in the first year). They also support the concancer in the treated group and two in the placebo group. The clusion that low-dose aspirin and statin treatment protect follow-up was not long enough to provide the outcome of the against this risk. 
